Inhalation Sciences to present the compelling results from the FDA-funded evaluation study of DissolvIt® at leading respiratory and inhalation drug development conferences

Huddinge, Sweden – August 20, 2026 – Inhalation Sciences AB, a specialized contract research organization focused on preclinical inhaled drug development, today announced that they will be presenting the results and significance of its FDA-funded evaluation of DissolvIt® at several leading scientific and industry meetings during August–October 2026.

These presentations will highlight the potential of DissolvIt as a biorelevant in vitro dissolution with the ability to support predictive translation from preclinical testing to clinical outcomes.

“The FDA-funded evaluation of DissolvIt represents an important milestone for Inhalation Sciences,” says Per Gerde, Founder and CSO of Inhalation Sciences. “We are now taking the findings to several important forums where we can engage directly with scientists, pharmaceutical companies, CRO’s and other stakeholders working to improve the predictability of inhaled drug development.”

Inhalation Sciences will present the FDA-funded DissolvIt evaluation study at three major industry and scientific meetings:

Rapid Response Partnership Vehicle (RRPV) General Membership Meeting in Arlington, MD, US 26–27 August 2026 , Poster Presentation

The RRPV brings together BARDA, government stakeholders, industry partners, academia, and innovators working to accelerate the development and delivery of innovative technologies.

Inhaled & Nasal Biologics I DNA Forum in Cambridge, UK 24-25 September 2026 , Poster Presentation

The Inhaled & Nasal BiologicsI DNA Forum brings together pharmaceutical and biotechnology companies, scientists, formulation and delivery specialists, CROs and other experts working on next-generation inhaled and nasal therapeutics.

MVIC Symposium, Lund, Sweden 21-22 October 2026, Podium Presentation

The MVIC Symposium is a specialist meeting for the inhalation drug-development community, bringing together pharmaceutical and biotechnology companies, scientists, technology providers, CROs and other stakeholders involved in inhaled and nasal medicines.

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.